Behavioral Wire covers the business and policy of mental health.
The beat spans pharma psychiatry, psychedelic-assisted therapy, cannabis and cannabinoid therapeutics, digital mental health, and the behavioral health services industry. Coverage centers on regulation, markets, research, and the people moving between them — written for the investors, operators, clinicians, regulators, and journalists who treat mental health as an industry rather than a self-help topic.
Why this publication exists
Nobody else covers mental health as one beat. Bloomberg covers pharma broadly and treats psychiatry as a footnote. STAT covers healthcare broadly and treats mental health as one specialty among many. Psychedelic Alpha covers psychedelics deeply but only psychedelics. Psychology Today is a consumer wellness publication, not industry coverage.
The synthesis between regulation, research, markets, and the structural questions that connect them — that is the gap Behavioral Wire fills.
What we cover
Pharma psychiatry. The SSRI and SNRI franchises, atypical antipsychotics, the novel-mechanism pipeline. Ketamine, esketamine, zuranolone, the GLP-1 psychiatric crossover. Drug development, FDA decisions, labels, reimbursement.
Psychedelics. Psilocybin, MDMA, ibogaine, ketamine-assisted therapy. Clinical trials, regulatory developments, state services programs, religious exemptions, the academic research landscape.
Cannabis. As a mental health market. Rescheduling, multi-state operators, cannabinoid pharmaceuticals, banking access, the research bottleneck that schedule classification has imposed.
Digital mental health. Telehealth psychiatry, therapy platforms, AI mental health, digital therapeutics. The reimbursement dynamics that decide which products survive.
Regulation, markets, research. Daily tracking of FDA, DEA, SEC, CMS, NIH, and Federal Register actions relevant to the field. Tracked equities across the covered universe. Original analysis of clinical trial readouts and academic research.
How we work
News reporting is held to standards of attribution and verification described in our methodology. Opinion is separately labeled and reflects an editorial point of view. The regulatory tracker is populated by automated polling of agency feeds plus editorial curation.
Behavioral Wire has no commercial relationships — sponsorship, advertising, consulting — with any company we cover. We do not accept payment for coverage. We do not preview articles with sources for approval.
Disclosures of any potential conflicts, including the editor's holdings in covered securities and affiliations with adjacent organizations, are maintained at our disclosures page and noted at the article level when relevant.
Who reads us
Behavioral Wire is read by investors evaluating mental health companies, operators running them, clinicians implementing the science, regulators shaping the rules, and journalists working adjacent beats. It is not written for therapy-seekers; readers in that position will find more useful resources at the National Alliance on Mental Illness, the Substance Abuse and Mental Health Services Administration, and clinical care providers.
If you are experiencing a mental health crisis, please contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Contact
Story tips, source outreach, and corrections can be sent to editor@behavioralwire.com. Confidential communications and document submissions can be sent via Signal at a number available on request.
Behavioral Wire is published independently from behavioralwire.com.